|
Fig 4 shows the hemolytic effects of 40% peg-400 with and without busulfan on human erythrocytes.
B dma: peg400: water : 40%, v v ; , in all solvents there was 3 mg ml of busulfan this clinically translates into a more predictable, and accurately reproducible cytotoxic effect as well as better control over the side effects and, therefore a higher degree of safety after busulfan-based chemotherapy.
2. Socie G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med. 1999; 341: 14-21. Socie G, Salooja N, Cohen A, et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood. 2003; 101: 3373-3385. Schover LR, Brey K, Lichtin A, et al. Knowledge and experience regarding cancer, infertility, and sperm banking in younger male survivors. J Clin Oncol. 2002; 20: 1880-1889. Anserini P, Chiodi S, Spinelli S, et al. Semen analysis following allogeneic bone marrow transplantation. Additional data for evidence-based counselling. Bone Marrow Transplant. 2002; 30: 447-451. Leiper AD, Stanhope R, Lau T, et al. The effect of total body irradiation and bone marrow transplantation during childhood and adolescence on growth and endocrine function. Br J Haematol. 1987; 67: 419-426. Salooja N, Szydlo RM, Socie G, et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet. 2001; 358: 271-276. Sanders JE, Hawley J, Levy W, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood. 1996; 87: 3045-3052. World Health Organisation. WHO Laboratory Manual for the Examination of Human Semen and Sperm Cervical Mucus Interaction. Cambridge: 1999. 10. Chatterjee R, Goldstone AH. Gonadal damage and effects on fertility in adult patients with haematological malignancy undergoing stem cell transplantation. Bone Marrow Transplant. 1996; 17: 5-11.
Exogenous RA Induces Stra8 Expression in Embryonic Testes. Testicular germ cells do not express Stra8 until after birth 2 ; , despite the fact that testicular cells express RARs during embryonic development 13 ; . Perhaps the germ cells of embryonic testes are not exposed to RA in vivo. To determine whether exogenous RA can induce Stra8 expression in embryonic testes, we assayed the gene's expression in gonads cultured with RA added to the medium. As expected, testes dissected at E12.5 and cultured for 2 days in control medium expressed no Stra8 Fig. 2A ; . By contrast, testes cultured with RA displayed abundant expression of Stra8 Fig. 2B ; . Although this RA-induced expression of Stra8 appeared to be limited to embryonic testis cords, we wanted to determine whether it was restricted to germ cells, where Stra8 is normally expressed in adult testes and embryonic ovaries. Embryonic gonads were depleted of germ cells by busulfan treatment 23 ; and then cultured with RA added to the medium. Stra8 expres2 of 6 pnas cgi doi 10.1073 pnas.0510813103.
Measurement of plasma busulfan levels is used to monitor its disposition, to ensure therapeutic drug levels, and may prevent excess drug toxicity, particularly to the hepatic vasculature, that is associated with high plasma busulfan levels.
A number of different reduced-intensity conditioning regimens were used and are listed in Table 2. The majority were fludarabine based 96% ; with the addition of either busulfan or melphalan. Seventy-nine patients received ATG as in vivo T-cell depletion, and 55 patients received alemtuzumab, most frequently in combination with fludarabine and melphalan. Peripheral blood was used as the source of cells in 183 patients and bone marrow in 46. Median cell doses for peripheral blood were 5.27 106 CD34 kg and for marrow 2.92 108 mononuclear cells kg. GvHD prophylaxis consisted of cyclosporin alone 56% ; , cyclosporin and methotrexate 30% ; , cyclosporin and steroid 2% ; , and methotrexate alone 3% ; and was unknown in 9 and butorphanol.
Et al. The influence nausea of.
Sit for sites, regulatory and managed care professionals that busulfan busulfan and byetta.
Busulfan for men
With a constant dose of busulfan , the total leukocyte count declines exponentially; a weekly plot of the leukocyte count on semi-logarithmic graph paper aids in predicting the time when therapy should be discontinued.
Busulfan review
Dose adjustment to achieve a predetermined target drug exposure. Therapeutic drug monitoring is important in high-dose chemotherapy administration, especially with agents such as oral busulfan that show erratic gastrointestinal absorption Grochow, 1993 ; . Variability in absorption and systemic exposure can lead to under- or overdosing. Targeted dosing is used to achieve optimal blood or plasma drug concentrations. The timing of drug sampling is critical for accurately determining plasma drug concentrations. Therapeutic drug monitoring usually is recommended for oral busulfan in the pediatric and adult populations to monitor and control pharmacokinetic variability and to assist with dose adjustments Lindley et al., 2004; McCune, Gibbs, & Slattery, 2000 however, therapeutic drug monitoring is compromised and is met with limited success with oral busulfan because as many as 25% of patients are not evaluable for pharmacokinetics Dix et al., 1996 ; . Targeted dosing is a valuable tool that can ensure consistency in dosing, maximum efficacy, and minimal toxicity; it also can minimize costs to patients and hospitals. Although targeted dosing is used with many drugs, the most reliable results are obtained with drugs that have a linear pharmacokinetic profile and achieve predictable blood concentrations Russell et al., 2002 ; . Pharmacokinetic studies of IV busulfan indicate that daily doses give predictable linear kinetics, with less variability than oral dosing Russell et al. ; . Day 1 and day 4 curves are very similar, with no accumulation of the drug from one dose to the next. Transplant centers generally use dose 1 pharmacokinetic results to assess plasma busulfan concentrations and to determine dose adjustments. Some institutions administer a test dose and wait for the results before beginning a full IV busulfan schedule and campral.
1. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A, WHI Investigators 2003 Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289: 32433253 2. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E 1998 Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen progestin Replacement Study HERS ; Research Group. JAMA 280: 605613 3. Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG, Burstein HJ, Eisen A, Lipkus I, Pfister DG, American Society of Clinical Oncology Breast Cancer Technology Assessment Working Group 2002 American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 20: 33283343 4. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T, ATAC Trialists' Group 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359: 21312139 5. Baum M 2005 Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now? Eur J Cancer 41: 16671677 6. Howell A, Buzdar A 2005 Are aromatase inhibitors superior to antiestrogens? J Steroid Biochem Mol Biol 93: 237247 7. Osborne CK 1998 Tamoxifen in the treatment of breast cancer. N Engl J Med 339: 16091618 8. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N 1998 Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 13711388.
Bleaching was multiphasic, summing contributions from multiple nucleophilic centers. In contrast to the trend in the reactions with simple nuclephiles, MeG + was generally more resistant to protein-mediated bleaching than MG + : and HSA contributed 78 and 38%, respectively, to the total color loss in MG + ; the corresponding contributions to the bleaching of MeG + were 16 and 15%. With both dyes IgG-mediated bleaching amounted to ca. 30%. It appeared that protein-borne sulphydryl groups could add to MG + but not to MeG + . The inferior reactivity of MeG + towards protein-SH may arise from hindered access of this nucleophile to the central carbon of the TAM + nucleus. The exceptional tendency of MG + add protein-SH needs to be accounted for. One possibility is that SH groups, excluded from the central carbon, add to the unsubstituted phenyl ring unique to MG + The results may be significant in relation to applied research on the use of TAM + s in the health sciences eg. CALI ; . P101 and camptosar.
Using meta-analysis. Despite all legitimate criticisms not to perform clinical trials without a placebo comparator, there are some issues within this special area of research that may justify the use of "historical" data. For the great majority of antiemetic drugs efficacy and effectiveness has been demonstrated in numerous prophylaxis trials with PONV setting and other indications where nausea and vomiting occur e.g. radio- and chemotherapy for cancer ; . There is no biological rationale why antiemetics should not work postoperatively when their activity has been proven intraoperatively. Furthermore, meta-analyses that have been performed on the few ; placebo-controlled treatment studies available have yielded results very similar to the numerous meta-analyses that have been per100.
That can be exempl ; hified by a ralnge of 5.8 to 15.3 seconds in. the case of appearance time recorded at the radial artery following the iijection of dye into the main pulmonary artery. The greatest part of this variability is mnost likely due to the biologic inltra-individual and and capecitabine!
Blood 75 12 ; : 2282-5, 199 chopra r, goldstone ah, mcmillan ak, et al: successful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan cyclophosphamide and unpurged marrow: the british autograft group experience.
TRADE NAMES: USAGE: TRAINING LEVEL: RESTRICTIONS: SPECIAL NOTES IMPORTANT POINTS: Percutaneous Nephrostomy, Pigtail catheter, others Used to drain fluid or pus from interior of body. ALL Levels Approved for transport only. Can not be manipulated or inserted by EMS personnel. If accidentally dislodged, place dressing over site and contact medical control and capsicum.
Oral busulfan administration gives a wide range of resulting plasma concentrations which influence the resulting toxicity profile, especially when the drug is used in supralethal doses as part of pretransplant conditioningregimens and busulfan.
|
